EpicentRx
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11099 N Torrey Pines Rd Ste 160, La Joll...Phone Number
(858) 947-6635Website
www.epicentrx.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About EpicentRx
Headquartered in La Jolla, California, EpicentRx is a company that focuses on immuno-oncology to work towards providing pharmaceuticals that are toxic to tumor cells and not toxic to patients.Explore more
EpicentRx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is EpicentRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
EpicentRx, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if EpicentRx had a recent Job posting/layoffs
Check out if EpicentRx is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when EpicentRx launches new products
Congratulate Masked Content for being promoted to Masked Content at EpicentRx
Funding: Get notified immidiatlly once EpicentRx has new funding data
Earning: See what the market has to say on EpicentRx recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if EpicentRx has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at EpicentRx
Find 2 more new buyers
Compare Similar Companies to EpicentRx
Compare insights from companies similar to EpicentRx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
EpicentRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
EpicentRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about EpicentRx.
EpicentRx financials insights
Gather financial insights about EpicentRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series D
$35M
EpicentRx Tech Stack
A closer look at the technologies used by EpicentRx
Most Recent Scoops
Promotion
Executive Move
Left Company
Executive Move
Dr. Corey Carter , Chief Executive Officer, has left the organization.
Promotion
Executive Move
New Hire
Executive Move
Franck Brinkhaus has been named Chief Financial Officer.
Executive Moves, New Hire, Personnel Moves
Funding
Funding
EpicentRx News & Media
EpicentRx Receives Highly Competitive US Department of Defense (DoD) Translational Award to Develop RRx-001 as a Neuroprotective Medical Countermeasure
The highly competitive award from the CDMRP Toxic Exposures Research Program will fund the development of EpicentRx's small molecule, RRx-001 (nibrozetone), as a neuroprotective agent and medical countermeasure against neurotoxic chemical exposures. TORREY PINES, Calif., Sept. 17, 2024...EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting
Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them. TORREY PINES, Calif.,...EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-β Trap Program in Checkpoint Inhibitor Resistant Patients at the 2024 AACR Meeting
Compelling clinical data demonstrate that AdAPT-001, which delivers a TGF-β trap to tumors, reverses established resistance to checkpoint inhibitors and makes checkpoint inhibitors more active SAN DIEGO, April 2, 2024 /PRNewswire/ -- EpicentRx, Inc, a clinical-stage biotechnology drug and...EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson's Disease and ALS/MND at Neuroscience 2023
TORREY PINES, Calif., Nov. 6, 2023 /PRNewswire/ -- EpicentRx, Inc. ("EpicentRx"), a clinical-stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, has been selected for oral and poster presentations at the prestigious Society for...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EpicentRx
Sign Up For FreeTo access detailed company insights
Headquartered in La Jolla, California, EpicentRx is a company that focuses on immuno-oncology to work towards providing pharmaceuticals that are toxic to tumor cells and not toxic to patients.... Read More
